Effects of sotagliflozin in diabetes, recent worsening HF


Diabetes patients with recent worsening heart failure who were treated with sotagliflozin for a median of 9 to 16 months had a 22% to 43% drop in mortality risk due to cardiovascular causes, as well as hospitalization or emergency visits for HF, compared with those who were treated with placebo, according to a study presented at the American College of Cardiology's Scientific Session. The findings, based on data from 11,784 people, also showed that sotagliflozin treatment was effective among all diabetes patients with any kind of heart failure.

Full story:

DiabetesPro SmartBrief

Diabetes Treatment News

Designed specifically for health care professionals, DiabetesPro SmartBrief is a FREE, daily e-mail newsletter. It provides the latest news, trends, and technology updates that matter most to health care professionals.